Search
- Page Path
-
HOME
> Search
Case Reports
- A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Ki Jeong Jeon, Sang Bu Ahn, Jin-Young Park, Cheol-Won Choi, Kwang-Mo Yang
-
J Liver Cancer. 2017;17(1):88-93. Published online March 31, 2017
-
DOI: https://doi.org/10.17998/jlc.17.1.88
-
-
Abstract
PDF
- Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of
advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under
3 months is far from clinical satisfactory and most patients experience disease progression within
6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment
failure of sorafenib was not established and there were no clear guidelines for salvage treatment
modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent
can be relatively effective and safe strategy that achieves promising rates of local and systemic
control in advanced HCC patients. Based on above suggestions, we herein offer our experience
of a case achieved complete remission by combination therapy of sorafenib and tegafur in the
patient with progressed disease after sorafenib therapy.
- A Case of Achieving Complete Remission with Stereotactic Body Radiation Therapy in Patients with Hepatocellular Carcinoma with Macrovascular Invasion after Repeated Transarerial Chemoembolization
-
Sang Youn Hwang, Seon-Mi Lee, Jong Woo Im, Ki Jeong Jeon, Sang Bu Ahn, Eun Kyeong Ji, Jin-Young Park, Cheol-Won Choi Choi, Gwang-Mo Yang
-
J Liver Cancer. 2016;16(2):123-128. Published online September 30, 2016
-
DOI: https://doi.org/10.17998/jlc.16.2.123
-
-
Abstract
PDF
- Transarterial chemoembolization (TACE) is the worldwide procedure performed for patients
with various stage hepatoceullar carcinoma (HCC), but is not yet considered as curative
treatment because of relatively high local recurrence rate. Moreover, many clinicians
frequently experience treatment failure (incomplete necrosis or stage progression etc.) after
repeated TACE, but no clear guidelines have been recommended about salvage treatment
modalities for this situation. Recently, studies for combination of radiation therapy and TACE
for HCC with TACE refractoriness have been tried and reported better therapeutic efficacy.
Based on above suggestions, we herein offer our experience of a patient with macrovascular
invasion developed after repeated TACE that achieve complete remission by stereotactic
body radiation therapy. Further study, maybe regarding a combination of locoregional and
systemic therapy, is necessary on how to manage HCC patients with TACE refractoriness.